P898: A PROSPECTIVE PHASE 2 STUDY TO ASSESS MINIMAL RESIDUAL DISEASE AFTER IXAZOMIB, LENALIDOMIDE, DEXAMETHASONE (IRD) TREATMENT FOR NEWLY DIAGNOSED TRANSPLANT ELIGIBLE MULTIPLE MYELOMA PATIENTS

Detalles Bibliográficos
Autores principales: Silvennoinen, Raija, Partanen, Anu, Waage, Anders, Pečeliūnas, Valdas, Schjesvold, Fredrik, Anttila, Pekka, Uttervall, Katarina, Säily, Marjaana, Putkonen, Mervi, Carlson, Kristina, Haukas, Einar, Sankelo, Marja, Szatkowski, Damian, Hansson, Markus, Marttila, Anu, Axelsson, Per, Svensson, Ronald, Lauri, Birgitta, Mikkola, Maija, Karlsson, Conny, Abelsson, Johanna, Ahlstrand, Erik, Sikiö, Anu, Klimkowska, Monika, Matuzeviciene, Reda, Hoyseter Fenstad, Mona, Ilveskero, Sorella, Nahi, Hareth
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Posters
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10430912/
http://dx.doi.org/10.1097/01.HS9.0000970496.55340.69
_version_ 1785091073332215808
author Silvennoinen, Raija
Partanen, Anu
Waage, Anders
Pečeliūnas, Valdas
Schjesvold, Fredrik
Anttila, Pekka
Uttervall, Katarina
Säily, Marjaana
Putkonen, Mervi
Carlson, Kristina
Haukas, Einar
Sankelo, Marja
Szatkowski, Damian
Hansson, Markus
Marttila, Anu
Axelsson, Per
Svensson, Ronald
Lauri, Birgitta
Mikkola, Maija
Karlsson, Conny
Abelsson, Johanna
Ahlstrand, Erik
Sikiö, Anu
Klimkowska, Monika
Matuzeviciene, Reda
Hoyseter Fenstad, Mona
Ilveskero, Sorella
Nahi, Hareth
author_facet Silvennoinen, Raija
Partanen, Anu
Waage, Anders
Pečeliūnas, Valdas
Schjesvold, Fredrik
Anttila, Pekka
Uttervall, Katarina
Säily, Marjaana
Putkonen, Mervi
Carlson, Kristina
Haukas, Einar
Sankelo, Marja
Szatkowski, Damian
Hansson, Markus
Marttila, Anu
Axelsson, Per
Svensson, Ronald
Lauri, Birgitta
Mikkola, Maija
Karlsson, Conny
Abelsson, Johanna
Ahlstrand, Erik
Sikiö, Anu
Klimkowska, Monika
Matuzeviciene, Reda
Hoyseter Fenstad, Mona
Ilveskero, Sorella
Nahi, Hareth
author_sort Silvennoinen, Raija
collection PubMed
description
format Online
Article
Text
id pubmed-10430912
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-104309122023-08-17 P898: A PROSPECTIVE PHASE 2 STUDY TO ASSESS MINIMAL RESIDUAL DISEASE AFTER IXAZOMIB, LENALIDOMIDE, DEXAMETHASONE (IRD) TREATMENT FOR NEWLY DIAGNOSED TRANSPLANT ELIGIBLE MULTIPLE MYELOMA PATIENTS Silvennoinen, Raija Partanen, Anu Waage, Anders Pečeliūnas, Valdas Schjesvold, Fredrik Anttila, Pekka Uttervall, Katarina Säily, Marjaana Putkonen, Mervi Carlson, Kristina Haukas, Einar Sankelo, Marja Szatkowski, Damian Hansson, Markus Marttila, Anu Axelsson, Per Svensson, Ronald Lauri, Birgitta Mikkola, Maija Karlsson, Conny Abelsson, Johanna Ahlstrand, Erik Sikiö, Anu Klimkowska, Monika Matuzeviciene, Reda Hoyseter Fenstad, Mona Ilveskero, Sorella Nahi, Hareth Hemasphere Posters Lippincott Williams & Wilkins 2023-08-08 /pmc/articles/PMC10430912/ http://dx.doi.org/10.1097/01.HS9.0000970496.55340.69 Text en Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially.
spellingShingle Posters
Silvennoinen, Raija
Partanen, Anu
Waage, Anders
Pečeliūnas, Valdas
Schjesvold, Fredrik
Anttila, Pekka
Uttervall, Katarina
Säily, Marjaana
Putkonen, Mervi
Carlson, Kristina
Haukas, Einar
Sankelo, Marja
Szatkowski, Damian
Hansson, Markus
Marttila, Anu
Axelsson, Per
Svensson, Ronald
Lauri, Birgitta
Mikkola, Maija
Karlsson, Conny
Abelsson, Johanna
Ahlstrand, Erik
Sikiö, Anu
Klimkowska, Monika
Matuzeviciene, Reda
Hoyseter Fenstad, Mona
Ilveskero, Sorella
Nahi, Hareth
P898: A PROSPECTIVE PHASE 2 STUDY TO ASSESS MINIMAL RESIDUAL DISEASE AFTER IXAZOMIB, LENALIDOMIDE, DEXAMETHASONE (IRD) TREATMENT FOR NEWLY DIAGNOSED TRANSPLANT ELIGIBLE MULTIPLE MYELOMA PATIENTS
title P898: A PROSPECTIVE PHASE 2 STUDY TO ASSESS MINIMAL RESIDUAL DISEASE AFTER IXAZOMIB, LENALIDOMIDE, DEXAMETHASONE (IRD) TREATMENT FOR NEWLY DIAGNOSED TRANSPLANT ELIGIBLE MULTIPLE MYELOMA PATIENTS
title_full P898: A PROSPECTIVE PHASE 2 STUDY TO ASSESS MINIMAL RESIDUAL DISEASE AFTER IXAZOMIB, LENALIDOMIDE, DEXAMETHASONE (IRD) TREATMENT FOR NEWLY DIAGNOSED TRANSPLANT ELIGIBLE MULTIPLE MYELOMA PATIENTS
title_fullStr P898: A PROSPECTIVE PHASE 2 STUDY TO ASSESS MINIMAL RESIDUAL DISEASE AFTER IXAZOMIB, LENALIDOMIDE, DEXAMETHASONE (IRD) TREATMENT FOR NEWLY DIAGNOSED TRANSPLANT ELIGIBLE MULTIPLE MYELOMA PATIENTS
title_full_unstemmed P898: A PROSPECTIVE PHASE 2 STUDY TO ASSESS MINIMAL RESIDUAL DISEASE AFTER IXAZOMIB, LENALIDOMIDE, DEXAMETHASONE (IRD) TREATMENT FOR NEWLY DIAGNOSED TRANSPLANT ELIGIBLE MULTIPLE MYELOMA PATIENTS
title_short P898: A PROSPECTIVE PHASE 2 STUDY TO ASSESS MINIMAL RESIDUAL DISEASE AFTER IXAZOMIB, LENALIDOMIDE, DEXAMETHASONE (IRD) TREATMENT FOR NEWLY DIAGNOSED TRANSPLANT ELIGIBLE MULTIPLE MYELOMA PATIENTS
title_sort p898: a prospective phase 2 study to assess minimal residual disease after ixazomib, lenalidomide, dexamethasone (ird) treatment for newly diagnosed transplant eligible multiple myeloma patients
topic Posters
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10430912/
http://dx.doi.org/10.1097/01.HS9.0000970496.55340.69
work_keys_str_mv AT silvennoinenraija p898aprospectivephase2studytoassessminimalresidualdiseaseafterixazomiblenalidomidedexamethasoneirdtreatmentfornewlydiagnosedtransplanteligiblemultiplemyelomapatients
AT partanenanu p898aprospectivephase2studytoassessminimalresidualdiseaseafterixazomiblenalidomidedexamethasoneirdtreatmentfornewlydiagnosedtransplanteligiblemultiplemyelomapatients
AT waageanders p898aprospectivephase2studytoassessminimalresidualdiseaseafterixazomiblenalidomidedexamethasoneirdtreatmentfornewlydiagnosedtransplanteligiblemultiplemyelomapatients
AT peceliunasvaldas p898aprospectivephase2studytoassessminimalresidualdiseaseafterixazomiblenalidomidedexamethasoneirdtreatmentfornewlydiagnosedtransplanteligiblemultiplemyelomapatients
AT schjesvoldfredrik p898aprospectivephase2studytoassessminimalresidualdiseaseafterixazomiblenalidomidedexamethasoneirdtreatmentfornewlydiagnosedtransplanteligiblemultiplemyelomapatients
AT anttilapekka p898aprospectivephase2studytoassessminimalresidualdiseaseafterixazomiblenalidomidedexamethasoneirdtreatmentfornewlydiagnosedtransplanteligiblemultiplemyelomapatients
AT uttervallkatarina p898aprospectivephase2studytoassessminimalresidualdiseaseafterixazomiblenalidomidedexamethasoneirdtreatmentfornewlydiagnosedtransplanteligiblemultiplemyelomapatients
AT sailymarjaana p898aprospectivephase2studytoassessminimalresidualdiseaseafterixazomiblenalidomidedexamethasoneirdtreatmentfornewlydiagnosedtransplanteligiblemultiplemyelomapatients
AT putkonenmervi p898aprospectivephase2studytoassessminimalresidualdiseaseafterixazomiblenalidomidedexamethasoneirdtreatmentfornewlydiagnosedtransplanteligiblemultiplemyelomapatients
AT carlsonkristina p898aprospectivephase2studytoassessminimalresidualdiseaseafterixazomiblenalidomidedexamethasoneirdtreatmentfornewlydiagnosedtransplanteligiblemultiplemyelomapatients
AT haukaseinar p898aprospectivephase2studytoassessminimalresidualdiseaseafterixazomiblenalidomidedexamethasoneirdtreatmentfornewlydiagnosedtransplanteligiblemultiplemyelomapatients
AT sankelomarja p898aprospectivephase2studytoassessminimalresidualdiseaseafterixazomiblenalidomidedexamethasoneirdtreatmentfornewlydiagnosedtransplanteligiblemultiplemyelomapatients
AT szatkowskidamian p898aprospectivephase2studytoassessminimalresidualdiseaseafterixazomiblenalidomidedexamethasoneirdtreatmentfornewlydiagnosedtransplanteligiblemultiplemyelomapatients
AT hanssonmarkus p898aprospectivephase2studytoassessminimalresidualdiseaseafterixazomiblenalidomidedexamethasoneirdtreatmentfornewlydiagnosedtransplanteligiblemultiplemyelomapatients
AT marttilaanu p898aprospectivephase2studytoassessminimalresidualdiseaseafterixazomiblenalidomidedexamethasoneirdtreatmentfornewlydiagnosedtransplanteligiblemultiplemyelomapatients
AT axelssonper p898aprospectivephase2studytoassessminimalresidualdiseaseafterixazomiblenalidomidedexamethasoneirdtreatmentfornewlydiagnosedtransplanteligiblemultiplemyelomapatients
AT svenssonronald p898aprospectivephase2studytoassessminimalresidualdiseaseafterixazomiblenalidomidedexamethasoneirdtreatmentfornewlydiagnosedtransplanteligiblemultiplemyelomapatients
AT lauribirgitta p898aprospectivephase2studytoassessminimalresidualdiseaseafterixazomiblenalidomidedexamethasoneirdtreatmentfornewlydiagnosedtransplanteligiblemultiplemyelomapatients
AT mikkolamaija p898aprospectivephase2studytoassessminimalresidualdiseaseafterixazomiblenalidomidedexamethasoneirdtreatmentfornewlydiagnosedtransplanteligiblemultiplemyelomapatients
AT karlssonconny p898aprospectivephase2studytoassessminimalresidualdiseaseafterixazomiblenalidomidedexamethasoneirdtreatmentfornewlydiagnosedtransplanteligiblemultiplemyelomapatients
AT abelssonjohanna p898aprospectivephase2studytoassessminimalresidualdiseaseafterixazomiblenalidomidedexamethasoneirdtreatmentfornewlydiagnosedtransplanteligiblemultiplemyelomapatients
AT ahlstranderik p898aprospectivephase2studytoassessminimalresidualdiseaseafterixazomiblenalidomidedexamethasoneirdtreatmentfornewlydiagnosedtransplanteligiblemultiplemyelomapatients
AT sikioanu p898aprospectivephase2studytoassessminimalresidualdiseaseafterixazomiblenalidomidedexamethasoneirdtreatmentfornewlydiagnosedtransplanteligiblemultiplemyelomapatients
AT klimkowskamonika p898aprospectivephase2studytoassessminimalresidualdiseaseafterixazomiblenalidomidedexamethasoneirdtreatmentfornewlydiagnosedtransplanteligiblemultiplemyelomapatients
AT matuzevicienereda p898aprospectivephase2studytoassessminimalresidualdiseaseafterixazomiblenalidomidedexamethasoneirdtreatmentfornewlydiagnosedtransplanteligiblemultiplemyelomapatients
AT hoyseterfenstadmona p898aprospectivephase2studytoassessminimalresidualdiseaseafterixazomiblenalidomidedexamethasoneirdtreatmentfornewlydiagnosedtransplanteligiblemultiplemyelomapatients
AT ilveskerosorella p898aprospectivephase2studytoassessminimalresidualdiseaseafterixazomiblenalidomidedexamethasoneirdtreatmentfornewlydiagnosedtransplanteligiblemultiplemyelomapatients
AT nahihareth p898aprospectivephase2studytoassessminimalresidualdiseaseafterixazomiblenalidomidedexamethasoneirdtreatmentfornewlydiagnosedtransplanteligiblemultiplemyelomapatients

Ejemplares similares